JP2023522402A - Mir-485-3pの発現を用いた診断方法 - Google Patents
Mir-485-3pの発現を用いた診断方法 Download PDFInfo
- Publication number
- JP2023522402A JP2023522402A JP2022564255A JP2022564255A JP2023522402A JP 2023522402 A JP2023522402 A JP 2023522402A JP 2022564255 A JP2022564255 A JP 2022564255A JP 2022564255 A JP2022564255 A JP 2022564255A JP 2023522402 A JP2023522402 A JP 2023522402A
- Authority
- JP
- Japan
- Prior art keywords
- mir
- seq
- nucleotides
- aspects
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063014633P | 2020-04-23 | 2020-04-23 | |
| US63/014,633 | 2020-04-23 | ||
| US202063047206P | 2020-07-01 | 2020-07-01 | |
| US63/047,206 | 2020-07-01 | ||
| US202063064305P | 2020-08-11 | 2020-08-11 | |
| US63/064,305 | 2020-08-11 | ||
| PCT/IB2021/053353 WO2021214720A1 (en) | 2020-04-23 | 2021-04-23 | Diagnostic methods using mir-485-3p expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023522402A true JP2023522402A (ja) | 2023-05-30 |
| JP2023522402A5 JP2023522402A5 (cg-RX-API-DMAC7.html) | 2024-05-07 |
Family
ID=78270846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564255A Pending JP2023522402A (ja) | 2020-04-23 | 2021-04-23 | Mir-485-3pの発現を用いた診断方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230167502A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4139488A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023522402A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230014705A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115917008A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021260191A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3175419A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021214720A1 (cg-RX-API-DMAC7.html) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090156459A1 (en) * | 2007-11-16 | 2009-06-18 | Pharmain Corporation | Cationic-Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2631292A3 (en) * | 2005-04-29 | 2013-11-20 | The Rockefeller University | Human microRNAs and methods for inhibiting same |
| JP6211511B2 (ja) * | 2011-04-18 | 2017-10-11 | ディアミール, エルエルシーDiamir, Llc | miRNAに基づくユニバーサルスクリーニングテスト(UST) |
| US9951330B2 (en) * | 2013-07-11 | 2018-04-24 | The Trustees Of Columbia University In The City Of New York | Micrornas that silence tau expression |
| CN105917005B (zh) * | 2013-11-18 | 2020-09-11 | 迪阿米尔有限责任公司 | 使用来自体液的miRNA检测和监控帕金森病(PD)的方法 |
| WO2018076015A1 (en) * | 2016-10-21 | 2018-04-26 | Thomas Jefferson University | Leveraging the presence or absence of mirna isoforms for recommending therapy in cancer patients |
| WO2018139759A1 (ko) * | 2017-01-26 | 2018-08-02 | 주식회사 바이오오케스트라 | 마이크로 rna를 이용한 알츠하이머병 진단방법 |
| WO2018139819A1 (ko) * | 2017-01-26 | 2018-08-02 | 주식회사 바이오오케스트라 | 마이크로 rna를 이용한 뇌 질환 예방 또는 치료 용도 |
| KR102105016B1 (ko) * | 2019-12-12 | 2020-04-28 | 주식회사 바이오오케스트라 | miR-485-3p를 이용한 알츠하이머병 진단 방법 |
-
2021
- 2021-04-23 WO PCT/IB2021/053353 patent/WO2021214720A1/en not_active Ceased
- 2021-04-23 KR KR1020227041165A patent/KR20230014705A/ko active Pending
- 2021-04-23 AU AU2021260191A patent/AU2021260191A1/en not_active Abandoned
- 2021-04-23 JP JP2022564255A patent/JP2023522402A/ja active Pending
- 2021-04-23 CN CN202180043984.XA patent/CN115917008A/zh active Pending
- 2021-04-23 EP EP21791933.1A patent/EP4139488A4/en not_active Withdrawn
- 2021-04-23 CA CA3175419A patent/CA3175419A1/en active Pending
- 2021-04-23 US US17/997,000 patent/US20230167502A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090156459A1 (en) * | 2007-11-16 | 2009-06-18 | Pharmain Corporation | Cationic-Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
Non-Patent Citations (1)
| Title |
|---|
| KOH HAN SEOK ET AL.: "Reducing miR485-3p ameliorates Alzheimer's disease pathology by regulation of amyloid beta and neuro", RESEARCH SQUARE, JPN6025024868, 26 March 2020 (2020-03-26), ISSN: 0005621359 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3175419A1 (en) | 2021-10-28 |
| EP4139488A4 (en) | 2024-05-22 |
| WO2021214720A1 (en) | 2021-10-28 |
| CN115917008A (zh) | 2023-04-04 |
| US20230167502A1 (en) | 2023-06-01 |
| EP4139488A1 (en) | 2023-03-01 |
| AU2021260191A1 (en) | 2022-11-17 |
| KR20230014705A (ko) | 2023-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108064227B (zh) | 用于调节τ蛋白表达的组合物 | |
| AU2017250017B2 (en) | Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof | |
| US20230304014A1 (en) | Mirna-485 inhibitor for huntington's disease | |
| US20230126157A1 (en) | Mirna-485 inhibitor for gene upregulation | |
| US20220081690A1 (en) | Use of mir-204 inhibitor to increase nurr1 protein expression | |
| JP2023513190A (ja) | タウオパチーを治療するためのmirna-485阻害剤の使用 | |
| JP7776924B2 (ja) | 変異FUSの発現を選択的に抑制する修飾siRNA | |
| KR20230014705A (ko) | Mir-485-3p 발현을 사용하는 진단 방법 | |
| US20230167447A1 (en) | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | |
| JP2024522216A (ja) | インフラマソーム関連疾患または障害を治療するためのmirna-485阻害剤の使用 | |
| JP2023513189A (ja) | 筋萎縮性側索硬化症(als)を治療するためのmirna-485阻害剤の使用 | |
| US20230119699A1 (en) | Diagnostic methods using sirt1 expression | |
| US20230121720A1 (en) | Diagnostic methods using pcg-1a expression | |
| WO2022003609A1 (en) | Snp diagnostic methods | |
| EP4634381A1 (en) | Compositions and methods for treating neurological diseases | |
| WO2024127317A1 (en) | Treating mitochondrial dysfunction with mirna-485 inhibitor | |
| WO2026055750A1 (en) | Chitinase antisense oligonucleotides | |
| WO2025126153A2 (en) | Compositions and methods for treating sod1-mediated neurological diseases | |
| WO2026105091A1 (en) | Compositions and methods to modulate transposable elements governing cell-state transitions | |
| WO2024161022A2 (en) | Compositions and methods for treating neurological diseases | |
| JP2024506868A (ja) | PSD95、シナプトフィジン、及びカスパーゼ-3の発現を調節するためのmiRNA-485阻害剤の使用 | |
| WO2023079499A1 (en) | Use of mir-485 inhibitors to treat age-associated diseases or conditions | |
| JP2024506869A (ja) | Nlrp3発現の異常に関連する疾患または障害を治療するためのmirna-485阻害剤の使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240423 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240423 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250618 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251211 |